AMENDMENTS TO THE CLAIMS

1. (Original) A method of preventing repolarisation or hyperpolarisation of a cell, wherein the cell contains a BK channel, including the administration to the cell of at least one pharmacologically effective amount of composition containing a BK channel antagonist containing the moiety shown in structure (I):



STRUCTURE (I)

or derivatives thereof.

2. (Original) The method as claimed in claim 1 wherein the derivatives of structure (I) are selected from the group consisting of: salts, analogues, isomers, and combinations thereof.

3. (Currently amended) The method as claimed in claim 1 ~~or claim 2~~ wherein the antagonist compound is selected from the group consisting of: lolitrem B, lolitrem A, lolitrem F, 31-*epi*lolitrem F, 31-*epi*lolitrem B, lolitrem E, lolitrem E acetate, lolitrem L, lolitrem G, lolitrem C, lolitrem M, lolitriol, lolitriol acetate, lolitrem N, lolitrem J, lolitrem H, lolitrem K, lolicine A and B, 30-desoxy lolitrem B-30α-ol, 30-desoxy-31-*epi*lolitrem B-30α-ol, 30-desoxylolitrem B-30-ene lolilline and combinations thereof.

4. (Currently amended) The method as claimed in claim 1 ~~or claim 2~~ wherein the antagonist compound is selected from the group consisting of:



STRUCTURE (II)

which includes compounds selected from the group consisting of: lolitrem B = 31α, 35β stereochemistry; 31-*epi*lolitrem B = 31β, 35β stereochemistry; lolitrem F = 31α, 35α; 31-*epi*lolitrem F = 31β, 35α;



STRUCTURE (III)

which includes compounds selected from the group consisting of: lolitrem E = 31α, 35β stereochemistry where R = H or acetate; lolitrem L = 31α, 35α stereochemistry where R = H or acetate;



STRUCTURE (IV)

which includes compounds selected from the group consisting of: lolitrem A = 31α, 35β stereochemistry; lolitrem G = 31α, 35α stereochemistry;



STRUCTURE (V)

which includes compounds selected from the group consisting of: lolitriol; = 31α, 35β stereochemistry where R_1 = H or acetate and R_2 = H; lolitrem N = 31α, 35α

stereochemistry where R_1=H or acetate and R_2=H; Lolitrem J = 31α, 35β stereochemistry where R_1 = H or acetate and R_2 = acetate;



STRUCTURE (VI)

which includes lolitrem H = 31α, 35β stereochemistry where R = H or acetate;



STRUCTURE (VII)

which includes lolitrem K = 31α, 35β stereochemistry, where R = H or acetate;



STRUCTURE (VIII)

which includes lolilline = 31α, 35β stereochemistry;



STRUCTURE (IX)

which includes lolitrem M = 31α, 35β stereochemistry;



STRUCTURE (X)

which includes lolicine A = 31α, 35β stereochemistry;



STRUCTURE (XI)

which includes lolicine B = 31α, 35β stereochemistry;



STRUCTURE (XII)

which includes compounds selected from the group consisting of: 30-desoxylolitrem B-30α-ol = 31α, 35β stereochemistry; 30-desoxy-31-*epi*lolitrem B-30α-ol = 31β, 35β stereochemistry;



STRUCTURE (XIII)

which includes 30-desoxylolitrem B-30-ene = 35β stereochemistry; and combinations of the above compounds.

5. (Currently amended) The method as claimed in ~~any of the above claims~~ Claim 1 wherein the composition further includes pharmaceutically and physiologically acceptable carriers.

6. (Currently amended) The method as claimed in claim [[4]] 5, wherein the pharmaceutically and physiologically acceptable carriers include components selected from the group including; fillers; excipients; modifiers; humectants; stabilisers; emulsifiers; diluents; and other formulation components such as a use of a lipid vehicle.

7. (Currently amended) The method as claimed in ~~any of the above claims~~ Claim 1, wherein the composition is administered in a form selected from the group including: an injection; a tablet; a capsule; a suppository; an injection; a suspension; a drink or tonic; a syrup; a

powder; an ingredient in solid or liquid foods; a nasal spray; a sublingual wafer; a transdermal patch; a transdermal injection; and combinations thereof.

8. (Currently amended) The method as claimed in ~~any of the above claims~~ Claim 1, wherein the BK channel antagonist compound or compounds are extracted from endophyte-infected plants and seeds.

9. (Currently amended) The method as claimed in ~~any of claims 1 to 6~~ Claim 1, wherein the BK channel antagonist compound or compounds are extracted from fungal cultures.

10. (Currently amended) The method as claimed in ~~any of claims 1 to 6~~ Claim 1, wherein the BK channel antagonist compound or compounds are derived by chemical synthesis.

11. (Currently amended) The method as claimed in ~~any of claims 1 to 6~~ Claim 1, wherein the BK channel antagonist compound or compounds are extracted from heterologous expression systems ~~including but not limited to bacteria, yeast, fungi, plants and animal cells~~.

12. (Currently amended) The method as claimed in claim [[7]] 8 wherein the perennial ryegrass seed is from *Lolium perenne*.

13. (Currently amended) The method as claimed in ~~any of the above claims~~ Claim 1, wherein the BK channel antagonist compound or compounds has activity against both alpha (α) subunit and alpha plus beta (β) accessory subunit (β_1 to β_4) channels.

14. (Currently amended) The method as claimed in ~~any of claims 1 to 4~~ Claim 1, wherein, for lolitrem B, the degree of antagonist inhibition is approximately 97% for a composition containing approximately 20nM lolitrem B.

15. (Currently amended) The method as claimed in ~~any of claims 1 to 4~~ Claim 1, wherein, for lolitrem B, the half maximal degree of antagonist inhibition (IC_{50}) is found for a composition containing approximately 3.7 ± 0.4 nM of lolitrem B.

16. (Currently amended) The method as claimed in ~~any of claims 1 to 4~~ Claim 1, wherein, for lolitriol, the degree of antagonist inhibition is approximately 100% for a composition containing approximately 1000 nM lolitriol.

17. (Currently amended) The method as claimed in ~~any of claims 1 to 4~~ Claim 1, wherein, for lolitriol, the half maximal degree of antagonist inhibition (IC_{50}) is found for a composition containing approximately 195 nM of lolitriol to inhibit α and β_1 BK channel activity

18. (Currently amended) The method as claimed in ~~any of claims 1 to 4~~ Claim 1, wherein, for lolitriol, the half maximal degree of antagonist inhibition (IC_{50}) is found for a composition containing approximately 536 ±16 nM of lolitriol to inhibit α and β_4 activity.

19. (Currently amended) The method as claimed in ~~any of claims 1 to 4~~ Claim 1, wherein, for 31-*epi*lolitrem B, the degree of antagonist inhibition is approximately 100% for a composition containing approximately 200nM 31-*epi*lolitrem B.

20. (Currently amended) The method as claimed in ~~any of claims 1 to 4~~ Claim 1, wherein, for 31-*epi*lolitrem B, the half maximal degree of antagonist inhibition (IC_{50}) is found for a composition containing approximately 58 ±6 nM of 31-*epi*lolitrem B to inhibit α and β_1 activity.

21. (Currently amended) The method as claimed in ~~any of claims 1 to 4~~ Claim 1, wherein, for 31-*epi*lolitrem B, the half maximal degree of antagonist inhibition (IC_{50}) is found for a composition containing approximately 49 nM of 31-*epi*lolitrem B to inhibit α and β_4 activity.

22. (Currently amended) The method as claimed in ~~any of claims 1 to 4~~ Claim 1, wherein, for lolitrem E, the degree of antagonist inhibition is approximately 100% for a composition containing approximately 100 nM lolitrem E.

23. (Currently amended) The method as claimed in ~~any of claims 1 to 4~~ Claim 1, wherein the antagonist effect of the composition is not able to be reversed by wash out for concentrations of 10 nM or greater of lolitrem B compound.

Claims 24-46 (Cancelled)

47. (Original) A composition that contains a pharmacologically effective amount of at least one BK channel antagonist compound containing the moiety shown in structure (VII):



STRUCTURE (VII)

which includes lolitrem K = 31α, 35β stereochemistry, where R = H or acetate.

48. (Original) A composition that contains a pharmacologically effective amount of at least one BK channel antagonist compound containing the moiety shown in structure (IX):



STRUCTURE (IX)

which includes lolitrem M = 31α, 35β stereochemistry.

49. (Original) A composition that contains a pharmacologically effective amount of at least one BK channel antagonist compound containing the moiety shown in structure (XII):



STRUCTURE (XII)

which includes compounds selected from the group consisting of: 30-desoxylolitrem B-30α-ol = 31α, 35β stereochemistry; 30-desoxy-31-*epi*lolitrem B-30α-ol = 31β, 35β stereochemistry.

50. (Original) A composition that contains a pharmacologically effective amount of at least one BK channel antagonist compound wherein the antagonist compound is structure (XIII):



STRUCTURE (XIII)

which includes 30-desoxylolitrem B-30-ene = 35β stereochemistry.

51. (New) The method as claimed in Claim 11 wherein the heterologous expression system is selected from the group consisting of bacteria, yeast, fungi, plants, and animal cells.